Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents.

Area of Science:

• Coordination Chemistry
• Nanotechnology
• Cancer Biology

Background:

• Ruthenium complexes are investigated for their therapeutic potential.
• Self-assembly is a key strategy for constructing complex molecular architectures.
• Cisplatin remains a cornerstone chemotherapy agent, but resistance and side effects necessitate novel alternatives.

Purpose of the Study:

• To synthesize and characterize novel ruthenium-containing nano-cage compounds.
• To evaluate the in vitro cytotoxicity of the synthesized compounds.
• To elucidate the mechanism of action of the most potent compound.

Main Methods:

• Preparation of ruthenium complexes 4 and 5.
• Self-assembly of complexes 4 and 5 with tripodal donor 1 to form nano-cage compounds 8 and 9.
• Cytotoxicity assays to compare compound 8 with cisplatin against tumor cell lines.
• Cell cycle analysis and apoptosis assays to determine the mechanism of action.

Main Results:

• Two novel nano-cage compounds, 8 and 9, were successfully synthesized.
• Compound 8 exhibited significantly enhanced cytotoxicity compared to cisplatin.
• Compound 8 effectively inhibited tumor cell proliferation.
• The anti-proliferative effect of compound 8 was mediated by induction of apoptosis and interference with cell cycle regulation.

Conclusions:

• Ruthenium-based nano-cage compounds represent a promising new class of anticancer agents.
• Compound 8 shows superior efficacy to cisplatin and warrants further investigation.
• The mechanism involves targeted disruption of cancer cell cycle progression and induction of programmed cell death.